DSMB recommends continuation of Curacyte’s Phase III PHOENIX trial

Date: 28/03/2011

Munich, Germany – Cyracyte announced today that the PHOENIX Phase III trial of PHP for distributive shock be continued after positive midpoint recommendation by the Data Safety Monitoring Board. For further details please be referred to the company website.